Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Ongoing Initiated Aug 1, 2024 (2 years ago)

Heparin (Heparin Sodium in 0.9% Sodium Chloride Injection)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing.

Cause type: Microbial contamination

Bacteria, mold, yeast or other microorganisms detected in the product. Contamination can occur from water systems, equipment or handling, and can cause infection. All microbial contamination recalls.

What was recalled

Heparin (Heparin Sodium in 0.9% Sodium Chloride Injection), 2,000 units per 1,000 mL (2 units/mL), 1000 mL Sterile Single Dose Container, Rx Only, Baxter USA, NDC 0338-0433-04

Affected NDC 0338-0433-04

Compare with the code on your package — it is the most precise check available.

Drug: Heparin

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Heparin Sodium in Sodium Chloride
Heparin Sodium
NDC 00338-0433
200 [USP'U]/100mL Injection, Solution
Intravenous
Baxter Healthcare Corporation Rx
Recalling firm
Baxter Healthcare Corporation
NDC code
0338-0433-04
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
Company announcement
Aug 5, 2024 · FDA notice with lot numbers
FDA recall number
D-0649-2024 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week.

Other Heparin recalls

See all

Other recalls by Baxter Healthcare Corporation

All 2024 recalls
Class I · High risk

Dextrose Injection

Presence of Particulate Matter: particulate matter identified as stainless steel particles in the solution.

Ongoing Particulate / foreign matter Baxter Healthcare Corporation NDC 00338-0719-06 D-0850-2026
Class II · Moderate risk

Daptomycin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0718-12 D-0821-2026